newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study